FIVE BURROUGHS WELLCOME AZT PATENTS UPHELD ON APPEAL; SIXTH IS REMANDED TO LOWER COURT FOR FURTHER PROCEEDINGS: NOVOPHARM WILL PRESS ON WITH LITIGATION
• By The Pink Sheet
Five of Burroughs Wellcome's six patents for AZT (Retrovir, zidovudine) are valid, the D.C. federal appeals court ruled Nov. 22. The three-judge panel reviewed a July 1993 New Bern, N.C. federal court ruling that Wellcome was the sole inventor of AZT. The defendants in the New Bern case, Barr and Novopharm, claimed that the National Institutes of Health should also have been named as an inventor. "On the facts before us, it is apparent that the district court correctly ruled against Barr and Novopharm as to five of the patents" (numbers 4,724,232, 4,828,838, 4,833,130, 4,837,208 and 4,818,538), the appeals court said.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.
In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.